Literature DB >> 17569121

Assessment of hepatic fibrosis in pediatric cases with hepatitis C virus in Egypt.

Manal A El-Hawary1, Mona S El-Raziky, Gamal Esmat, Hanan Soliman, Amr Abouzied, Maissa El-Raziky, Wafaa El-Akel, Rokaya El-Sayed, Fatma Shebl, Abdel-Aziz Shaheen, Hanaa El-Karaksy.   

Abstract

AIM: To assess hepatic fibrosis and factors associated with its progression in children with HCV infection.
METHODS: At the Hepatology Unit, Cairo University Children's Hospital, a single liver biopsy was performed to 43 children with HCV infection after an informed consent between 1998-2004. Their mean age at liver biopsy was 8.67 +/- 4.3 years.
RESULTS: Among the 43 patients' biopsies, 12 (27.9%) were having no fibrosis, 20 (46.5%) mild fibrosis and 11 (25.6%) moderate to severe fibrosis. The median time for development of fibrosis was estimated to be 5.5 years. Developing fibrosis was significantly associated with shorter duration from first detected ALT elevation to biopsy (12 mo vs 1.2 mo, P=0.015) and having higher levels of direct serum bilirubin (0.3 mg/dL vs 0.5 mg/dL, P=0.048). No association was found between fibrosis stage and the presence of co-morbid conditions (P=0.33).
CONCLUSION: Hepatic fibrosis was present in 72.1% of children with HCV infection. The development of fibrosis was associated with higher levels of direct serum bilirubin. There was no significant association between fibrosis and age, duration of infection, risk factors, co-morbid conditions and most biochemical parameters.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17569121      PMCID: PMC4395637          DOI: 10.3748/wjg.v13.i20.2846

Source DB:  PubMed          Journal:  World J Gastroenterol        ISSN: 1007-9327            Impact factor:   5.742


  44 in total

1.  High incidence of allograft cirrhosis in hepatitis C virus genotype 1b infection following transplantation: relationship with rejection episodes.

Authors:  M Prieto; M Berenguer; J M Rayón; J Córdoba; L Argüello; D Carrasco; A García-Herola; V Olaso; M De Juan; M Gobernado; J Mir; J Berenguer
Journal:  Hepatology       Date:  1999-01       Impact factor: 17.425

2.  Pathology of chronic hepatitis C in children. Child Liver Study Group of Japan.

Authors:  M Kage; T Fujisawa; K Shiraki; T Tanaka; T Fujisawa; A Kimura; K Shimamatsu; E Nakashima; M Kojiro; M Koike; Y Tazawa; D Abukawa; M Okaniwa; H Takita; A Matsui; T Hayashi; T Etou; S Terasawa; K Sugiyama; H Tajiri; A Yoden; Y Kajiwara; M Sata; Y Uchimura
Journal:  Hepatology       Date:  1997-09       Impact factor: 17.425

3.  Prevalence and clinical outcome of hepatitis C infection in children who underwent cardiac surgery before the implementation of blood-donor screening.

Authors:  M Vogt; T Lang; G Frösner; C Klingler; A F Sendl; A Zeller; B Wiebecke; B Langer; H Meisner; J Hess
Journal:  N Engl J Med       Date:  1999-09-16       Impact factor: 91.245

4.  Slow progression rate of fibrosis in hepatitis C virus patients with persistently normal alanine transaminase activity.

Authors:  P Mathurin; J Moussalli; J F Cadranel; V Thibault; F Charlotte; P Dumouchel; A Cazier; J M Huraux; B Devergie; M Vidaud; P Opolon; T Poynard
Journal:  Hepatology       Date:  1998-03       Impact factor: 17.425

5.  Nonalcoholic steatohepatitis: a proposal for grading and staging the histological lesions.

Authors:  E M Brunt; C G Janney; A M Di Bisceglie; B A Neuschwander-Tetri; B R Bacon
Journal:  Am J Gastroenterol       Date:  1999-09       Impact factor: 10.864

6.  Hepatitis C virus infection in Egyptian children: single centre experience.

Authors:  M S El-Raziky; M El-Hawary; N El-Koofy; S Okasha; M Kotb; K Salama; G Esmat; M El-Raziky; A M Abouzied; H El-Karaksy
Journal:  J Viral Hepat       Date:  2004-09       Impact factor: 3.728

7.  Non-invasive markers and predictors of severity of hepatic fibrosis in HCV patients at Sharkia Governorate, Egypt.

Authors:  Eman el-Shorbagy; Afefy F Afefy; Ibrahem A Ibrahem; Amal M Mangoud; Mostafa H Eissa; Essam I Sabee; Seham Mahrous; Amal Abdel-Monem; Alaa Ismail; Tosson A Morsy; Samia Etewa; Essam Nor Edin; Yousry Mostafa; Yousry Abouel-Magd; Mahmoud el-Sedawy; Hosnia Ragab; Hanan el-Tokhy; Mostafa I Hassan; Khalid Lakouz; Khalid Abdel-Aziz; Gaber el-Hady; Mahmoud Saber
Journal:  J Egypt Soc Parasitol       Date:  2004-04

8.  Concurrence of histologic features of steatohepatitis with other forms of chronic liver disease.

Authors:  Elizabeth M Brunt; Sunil Ramrakhiani; Barry G Cordes; Brent A Neuschwander-Tetri; Christine G Janney; Bruce R Bacon; Adrian M Di Bisceglie
Journal:  Mod Pathol       Date:  2003-01       Impact factor: 7.842

9.  Iron overload in children who are treated for acute lymphoblastic leukemia estimated by liver siderosis and serum iron parameters.

Authors:  Päivi Halonen; Jorma Mattila; Pauli Suominen; Tarja Ruuska; Matti K Salo; Anne Mäkipernaa
Journal:  Pediatrics       Date:  2003-01       Impact factor: 7.124

10.  Factors associated with severity of hepatic fibrosis in people with chronic hepatitis C infection.

Authors:  Mark Danta; Gregory J Dore; Lisa Hennessy; Yueming Li; Chris R Vickers; Hugh Harley; Meng Ngu; William Reed; Paul V Desmond; William Sievert; Geoff C Farrell; John M Kaldor; Robert G Batey
Journal:  Med J Aust       Date:  2002-09-02       Impact factor: 7.738

View more
  2 in total

Review 1.  Hepatitis C genotype 4: The past, present, and future.

Authors:  Tawhida Y Abdel-Ghaffar; Mostafa M Sira; Suzan El Naghi
Journal:  World J Hepatol       Date:  2015-12-08

2.  Sofosbuvir and Ribavirin Therapy for Children Aged 3 to <12 Years With Hepatitis C Virus Genotype 2 or 3 Infection.

Authors:  Philip Rosenthal; Kathleen B Schwarz; Regino P Gonzalez-Peralta; Chuan-Hao Lin; Deidre A Kelly; Scott Nightingale; William F Balistreri; Sanjay Bansal; Maureen M Jonas; Benedetta Massetto; Diana M Brainard; Chia-Hsiang Hsueh; Jiang Shao; Bandita Parhy; Suzanne Davison; Cornelia Feiterna-Sperling; Lynette A Gillis; Giuseppe Indolfi; Etienne M Sokal; Karen F Murray; Stefan Wirth
Journal:  Hepatology       Date:  2019-08-13       Impact factor: 17.425

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.